Skip to content

Press Releases and Events

PRESS RELEASES AND EVENTS

Archived Events

There are currently no events to display.

Press Releases

Date Title and Summary View
Toggle Summary Intra-Cellular Therapies Announces Favorable Results From Long-Term Open-Label Safety Switching Study With Lumateperone in Patients with Schizophrenia at the 57th Annual Meeting of the American College of Neuropsychopharmacology
Favorable safety results following administration of lumateperone for up to one year treatment duration are consistent with and extend the safety and tolerability profile previously reported in short-term trials Intra-Cellular Therapies to Host a Conference Call Wednesday, December 12, 2018 at 8:30
View HTML
Toggle Summary Intra-Cellular Therapies Announces FDA Acceptance of New Drug Application for Lumateperone for the Treatment of Schizophrenia
NEW YORK , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration ( FDA ) has accepted for review
View HTML
Toggle Summary Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2018 Financial Results
NEW YORK , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today provided a corporate update and announced its financial results for the third quarter
View HTML
Toggle Summary Intra-Cellular Therapies to Host Third Quarter 2018 Financial Results Conference Call and Webcast
NEW YORK , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m.
View HTML
Toggle Summary Intra-Cellular Therapies Announces Favorable Safety Profile for ITI-214 in a Phase 1/2 Clinical Trial in Patients with Parkinson’s Disease
Results show ITI-214 is associated with clinical signs consistent with improvements in motor symptoms and dyskinesias               NEW YORK , Oct. 23, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) today announced topline results from the Company’s Phase 1/2 clinical study
View HTML
Toggle Summary Intra-Cellular Therapies Presents Results from ITI-214 Phase 1/2 Clinical Trial in Patients with Parkinson’s Disease at 2018 American Neurological Association Annual Meeting
NEW YORK , Oct. 17, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced it will present top line results from the Company’s Phase 1/2 clinical study
View HTML
Toggle Summary Intra-Cellular Therapies Appoints Mark Neumann as Executive Vice President, Chief Commercial Officer
NEW YORK , Oct. 16, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the appointment of Mark Neumann as Executive Vice President, Chief
View HTML
Toggle Summary Intra-Cellular Therapies Completes Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia
NEW YORK , Sept. 28, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the Company has completed the rolling submission of its New Drug
View HTML
Toggle Summary Intra-Cellular Therapies to Present at the Cantor Fitzgerald Global Healthcare Conference
NEW YORK , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates , Ph.D., Chief Executive Officer and Chairman, is
View HTML
Toggle Summary Intra-Cellular Therapies Appoints Michael Olchaskey as Senior Vice President, Head of Regulatory Affairs
NEW YORK , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced the appointment of Michael Olchaskey, PharmD as Senior Vice President, Head of
View HTML
Toggle Summary Intra-Cellular Therapies Appoints Dr. Suresh Durgam as Senior Vice President, Late Stage Clinical Development and Medical Affairs
NEW YORK , Aug. 20, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced the expansion of the senior leadership team with the appointment of Suresh Durgam
View HTML
Toggle Summary Intra-Cellular Therapies Provides Corporate Update and Reports Second Quarter 2018 Financial Results
NEW YORK , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today provided a corporate update and announced its financial results for the second quarter
View HTML
Toggle Summary Intra-Cellular Therapies to Host Second Quarter 2018 Financial Results Conference Call and Webcast
NEW YORK , July 26, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced day announced that it will host a conference call and live webcast discussion
View HTML
Toggle Summary Intra-Cellular Therapies Announces Publication Highlighting ITI-214 Mechanism of Action and Describing Positive Results in Preclinical Models of Heart Failure
Data indicates ITI-214 acts by a novel mechanism of action via modulation of the adenosine A 2B receptor signaling pathway ITI-214 increases cardiac contractility without increasing intracellular calcium These data may represent an important therapeutic advancement for the treatment of heart
View HTML
Toggle Summary Intra-Cellular Therapies Initiates Rolling Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia
NEW YORK , June 06, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the initiation of a rolling submission of its New Drug Application (NDA) with
View HTML